Precision Business Insights
Portfolio

 

Europe Anti diabetic Biosimilars Market

: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Europe Anti diabetic Biosimilars Market By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, α-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

 

Europe Anti diabetic Biosimilars Market Outline

 

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

 

Market Dynamics: Europe Anti diabetic Biosimilars Market

Drivers:

  • Increase in the prevalence of diabetic patients due to change in lifestyle
  • Patent expiries block buster drugs and promising product pipeline
  • Rise in R&D activities for the innovation of Insulin biosimilars

Restraints:

  • High cost and longer duration of R&D activities
  • Stringent regulatory policies
  • Complexity in development of biosimilars

 

Market Scope

 

Based on the drug class, Europe market is segmented into the following:

  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • α-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others

 

Based on the disease type, Europe market is segmented into the following:

  • Type-I Diabetes
  • Type-II Diabetes

 

Based on the distribution channel, Europe market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Based on the Country, Europe market is segmented into the following:

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

 

Competition Assessment

 

  • Merck Sharp & Dohme Corporation (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key marketdevelopments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Merck Sharp & Dohme Corporation (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

$ 2,000.00$ 6,900.00
Region Europe
Clear selection

Select License Type

Databank Europe $ 2,000.00
spinner
Single User Europe $ 3,100.00
spinner
Multiple User Europe $ 4,600.00
spinner
Corporate UserEurope $ 6,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials